1988
Foundation
of curasan Pharma GmbH by Hans-Dieter Rössler.
Product launch of local anesthetics and antibiotics
1997
CE Certification
of CERASORB® in dentistry and maxillofacial surgery
1998
Start
of clinical studies with CERASORB®.
1999
First
clinical results on CERASORB®.
2000
Conversion
of the GmbH into an AG and IPO on July 20
2001
Product
launch of stypro®
2002
FDA certification
of CERASORB® in orthopedics and traumatology
2003
Product launch
of CERASORB® Ortho in the USA.
FDA certification of CERASORB® production facility in Frankfurt, Germany
2004
Product launch
of CERASORB® M
2005
Product launch
of the hyaluronic acid injection Curavisc®.
2009
CE certification
of Osbone®
Foundation of curasan, Inc. USA
2010
Opening
of the new research, development and production facility in Frankfurt, Germany
2011
FDA certification
for Osbone® Dental in the USA.
CE certification for Osseolive®.
2012
CE certification
for CERASORB® Paste
2013
FDA certification
for Osseolive® Dental.
CE certification for Ceracell® Foam.
2014
Product launch
of CERASORB® Foam in the dental sector.
2018
FDA certification
for CERASORB® Ortho Foam in the USA.
Shane Ray new President of curasan, Inc.
2018
Celebration
of 30 years curasan.
2020
new CEO
Dr. Alexander Baratta
2021
new CEO
Dr. Dirk Dembski new CEO.
Dr. Alexander Baratta replaces Dr. Detlef Wilke on the Supervisory Board.
Sale of curavisc to bioventus: curasan strengthens its core business.
Headquarter move to Frankfurt, Germany.
2022
Foundation
of the subsidiary novaxomx GmbH with the aim of developing osteoinductive growth factors.
Product launch CERASORB® CPC Bone Void Filler.
Product launch BoneFlo®.
2023
New
Corporate Design and branding.
Product launch CERASORB® Bioactive.
25 years of clinical evidence: CERASORB®.